Clinical trials: ILD
Telerehabilitation, Exercise
Effectiveness of Telerehabilitation-Assisted Exercise Training
This study aimed to evaluate the effectiveness of asynchronously implemented telerehabilitation-supported respiratory physiotherapy and function-oriented trunk stabilization exercises, which have not been previously applied in…
- Trial name
- NCT07034989
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people
- Sponsor
- Zülal TATAR
Lung Fibrosis Interstitial
Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)
The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient…
- Trial name
- FILIP (NCT07457463)
- Testing
- Blended patient education and self-management programme
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Interstitial Lung Disease, Chronic Cough
Chronic COUGH Management in Interstitial Lung DisEase
Interstitial Lung Disease (ILD) includes chronic, disabling and progressive respiratory conditions marked by lung inflammation and fibrosis.
- Trial name
- COUGH-LESS (NCT06782893)
- Testing
- Non-pharmacological cough control therapy, Healthy lifestyle
- Where
- Portugal
- Volunteers
- 60 people
- Sponsor
- Aveiro University
Interstitial Lung Diseases
Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)
Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous and lethal pathological process with limited therapeutic options, which is the most common and severe of the idiopathic interstitial pneumonias (IIPs).
- Trial name
- NCT02509364
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Idiopathic Pulmonary Fibrosis
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment…
- Trial name
- NCT02788474
- Testing
- nintedanib
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 347 people
- Sponsor
- Boehringer Ingelheim
Telomere Biology Disorders, Dyskeratosis Congenita
Nucleoside Therapy in Patients With Telomere Biology Disorders
The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders.
- Conditions
- Telomere Biology Disorders, Dyskeratosis Congenita, Revesz Syndrome, Hoyeraal Hreidarsson Syndrome
- Trial name
- NCT06817590
- Testing
- deoxycytidine, deoxythymidine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Suneet Agarwal
Breast Neoplasms
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
The purpose of the study is to: compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the…
- Trial name
- NCT07096024
- Testing
- palbociclib plus fulvestrant, fulvestrant
- Where
- United States
- Volunteers
- 95,637 people
- Sponsor
- Pfizer
Anti-Glomerular Basement Membrane Disease
Anti-Glomerular Basement Membrane Disease
This study aims to clarify the prognosis of the rare but severe condition anti-glomerular basement membrane disease (anti-GBM disease also known as Goodpastures disease).
- Trial name
- PRAGMATIC (NCT07018024)
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Region Skane
Chronic Pulmonary Disease
Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study
Chronic pulmonary disease like interstitial lung disease (ILD) and chronic obstructive lung disease (COPD) are a significant health problem in Canada and around the world.
- Trial name
- Tele-RehaB (NCT04658979)
- Testing
- Pulmonary tele-rehabilitation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Pulmonary Sarcoidosis
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
"The reference treatment for pulmonary sarcoidosis is prolonged systemic corticosteroid therapy, which improves dyspnea, fatigue and respiratory function.
- Trial name
- QUIDOSE (NCT05247554)
- Testing
- Hydroxychloroquine + low-dose prednisone, Prednisone
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Fibrosis, Interstitial Lung Disease
Pulmonary Fibrosis Foundation Community Registry
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT05382572
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Pulmonary Fibrosis Foundation
Chronic Respiratory Disease, Hypoxia, Altitude
Validation of a Predictive Score for HAST
Patients with chronic lung diseases travelling by plane often suffer with symptoms related to lower oxygen levels they are exposed to while flying.
- Conditions
- Chronic Respiratory Disease, Hypoxia, Altitude, COPD, ILD
- Trial name
- NCT03728595
- Testing
- Venepuncture, Spirometry, Hypoxic altitude simulation test (HAST)
- Where
- United Kingdom
- Volunteers
- 96 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Fibrosis Lung, Respiratory Therapy
Automated Oxygen Titration During Walking in Patients With Lung Fibrosis (OXYWILD)
Fibrotic lung disease is a group of severe scarring lung diseases with a dismal prognosis, often leading to respiratory failure and need for oxygen treatment.
- Trial name
- OXYWILD (NCT06465654)
- Testing
- Automated variable dose oxygen treatment, Fixed dose oxygen treatment
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Janne Hastrup Jensen
Pulmonary Hypertension, Interstitial Lung Disease
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with…
- Trial name
- NCT05649722
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 22 sites in Argentina, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Insmed Incorporated
Pneumonia, Interstitial
Study Testing Convalescent Plasma vs Best Supportive Care
Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.
- Trial name
- NCT04333251
- Testing
- high-titer anti-Sars-CoV-2 plasma, oxygen therapy
- Sponsor
- Baylor Research Institute
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Graft Dysfunction, Interstitial Fibrosis
Novartis Everolimus Transition
Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone will be associated with improvement in…
- Trial name
- NCT02096107
- Testing
- Everolimus, Standard of Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Idiopathic Pulmonary Fibrosis
Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish…
- Trial name
- NCT03281200
- Testing
- L - Antineoplastic and immunomodulating agents, L01 - Antineoplastic agents, L01X - Other antineoplastic agents
- Where
- Spain
- Volunteers
- 172 people
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer, Coronary Artery Disease
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.
- Conditions
- Diabetic Foot Ulcer, Coronary Artery Disease, Parenchymatous; Pneumonia, Kidney Stone
- Trial name
- SPEQUA (NCT04328181)
- Testing
- Spectral Photon Counting Computed Tomography (SPCCT), DECT (Dual Energy CT)
- Where
- France
- Volunteers
- 339 people
- Sponsor
- Hospices Civils de Lyon
Sarcoidosis, Pulmonary
Pirfenidone for Progressive Fibrotic Sarcoidosis
Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis
- Trial name
- PirFS (NCT03260556)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati